
Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Search results
Mirugen – Unlocking the Power of Retina Regeneration
Our Medical Advisory Board (MAB) advises our Board of Trustees in order that they can approve grants for research projects.
Many inherited sight loss conditions occur when cells in the retina, which is the light-sensitive region at the back of the eye, deteriorate in an unpredictable way. These conditions are often referred to as inherited retinal dystrophies.
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
During our 50th Anniversary year, get involved in our annual Raffle! You could win 5 incredible prizes and support Retina UK at the same time.
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Do you want to win up to £25,000 and feel good about supporting people with inherited progressive sight loss?!
CRISPR gene editing leads to improvements in vision for people with inherited blindness, clinical trial shows.